Oligonucleotide therapies for nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis (NASH) represents a severe disease subtype of nonalcoholic fatty liver disease (NAFLD) that is thought to be highly associated with systemic metabolic abnormalities. It is characterized by a series of substantial liver damage, including hepatocellular steatosis, inflamma...
Saved in:
Main Authors: | Sixu Li (Author), Feng Xiong (Author), Songbo Zhang (Author), Jinghua Liu (Author), Guangping Gao (Author), Jun Xie (Author), Yi Wang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ferroptosis plays a novel role in nonalcoholic steatohepatitis pathogenesis
by: Fei Xiong, et al.
Published: (2022) -
Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023) -
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
by: Daniel Lindén, et al.
Published: (2019) -
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
by: Milic S, et al.
Published: (2015) -
Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy
by: Emmanuel A. Tsochatzis, et al.
Published: (2009)